Eurobiomed is pleased to invite you to the 3rd edition of Immunology Days, to be held at the EMD in Marseille. Under the theme “ All committed to the development of immune therapies against cancer, inflammatory and infectious diseases ”, this year’s event will bring together key players from research and industry to advance innovations in immunology. This unique event offers a space dedicated to exchanging knowledge and sharing scientific advances in the field of immunology. Participants will be able to attend presentations of innovative projects and discover new perspectives on immune therapies, all in a setting conducive to scientific interaction.
PROGRAM
Welcome
Introduction, Eric VACARESSE - President, Eurobiomed
Words from local authorities
MIB, an International Biocluster in Immunology – an update
Key Note Sanofi : A global strategy targeting immune-diseases
Part 1: MIB’s ambition to accelerate, target discovery, validation and success
B-SCREEN, a bed-to-bench approach to revealed original targets,
Pr Noémie JOURDE-CHICHE - MD PhD, Aix-Marseille Université & MI-mAbs (name to be confirmed)
CELL SCALE, a platform for innovative formats
C2IT, When IPC and APHM join forces to reinforce clinical trials in immunology
Lunch & Networking
Part 2: A hub of industrial innovation
Remora Biotech Venture Builder
Mr David BECHARD- PhD CEO, Nanomunity
ImCheck
(name to be confirmed)
Part 3: A collaborative network to support industrial drug development
GTP bioways
Mr Eric DEVIC - PhD CEO, GTP Bioways
New opportunities for democratizing the use of flow cytometry
Mr Fabrice MALERGUE- PhD Senior Staff Research Scientist, Beckman Coulter Life Sciences/ Immunotech
Networking
End
About MIB
Located at the center of Marseille, home of immunology research for over 40 years, the mission of MIB is to develop and implement cooperation between all stakeholders of tomorrow’s immunology at the national and international levels. Researchers, hospital practitioners, biotechs & pharma innovators, investors, students and public authorities will benefit from a dynamic environment (technology platforms, immunology start-up studios, support for SMEs and larger companies, etc.) and complementary expertise to develop cutting-edge immune-based therapies and new diagnostic tools. With a budget of €97 million as part of the France 2030 Plan, MIB aims to accelerate translational research in immunology, focusing on four therapeutic areas: oncology, infectiology, autoimmune and inflammatory diseases, for the benefit of patients.
MIB partners :